EARLY ACS (TIMI 39)

Protocol Design

*Age 50-54 with hx of CAD & either ↑ MB or Tn or new STD can be enrolled

≥ 2 of the following:
1. ↑ MB or Tn
2. New STD ≥ 1mm
3. Age ≥ 60*

Eptifibatide 180/2/180 → Matching Placebo

Angiography > 12 Hrs Later

Optional Study Drug in Cath Lab
Blinded Placebo / Eptifibatide

Primary Endpoint: Death/MI/Urgent Revasc/Thrombotic Bailout at 96h
Secondary Endpoint: Death/MI at 30 days
**EARLY ACS (TIMI 39)**

### Results

- **OR 0.92 (0.80, 1.06)**  
  - **P = 0.23**

- **OR 0.89 (0.79, 1.01)**  
  - **P = 0.072**

- **OR 1.75 (1.43, 2.13)**  
  - **P < 0.001**

**Bar Chart Description:**

- **D/MI/RI → UR/TBO at 96h**
  - N = 4684 (Delayed Provisional: 10.0%, Early Routine: 9.3%)
  - N = 4722 (Delayed Provisional: 9.3%, Early Routine: 9.3%)

- **D/MI at 30d**
  - N = 4684 (Delayed Provisional: 12.3%, Early Routine: 11.2%)
  - N = 4722 (Delayed Provisional: 11.2%, Early Routine: 11.2%)

- **TIMI Major/Minor Bleeding at 120h**
  - N = 4643 (Delayed Provisional: 3.4%, Early Routine: 5.7%)
  - N = 4686 (Delayed Provisional: 3.4%, Early Routine: 5.7%)

**Definitions:**

- D = Death; MI = Myocardial Infarction; RI → UR = Recurrent Ischemia leading to Urgent Revascularization; TBO = Thrombotic Bailout with bolus therapy
- Opposite to initial study-group assignment